Content about Avanir Pharmaceuticals

June 11, 2012
FDA accepts Avanir's IND application for AVP-923

Avanir Pharmaceuticals confirmed that the Food and Drug Administration has accepted the company's investigational new drug application for an Alzheimer's disease drug.

ALISO VIEJO, Calif. — Avanir Pharmaceuticals confirmed that the Food and Drug Administration has accepted the company's investigational new drug application for an Alzheimer's disease drug.

Avanir said the FDA's acceptance of AVP-923, an investigational treatment of agitation in patients with Alzheimer's disease, marks the fourth IND for the AVP-923 program. The drug will be evaluated in a phase-2 clinical trial during third quarter 2012.

November 10, 2011
Genzyme names leaders of MS, rare diseases units

Genzyme has named leaders of two units that are part of the core focus of the drug maker's business.

CAMBRIDGE, Mass. — Genzyme has named leaders of two units that are part of the core focus of the drug maker's business.

Bill Sibold, former chief commercial officer at Avanir Pharmaceuticals, was appointed to serve as head of the multiple sclerosis business, while Rogério Vivaldi, who most recently served as president of Genzyme’s renal and endocrinology business, now is the head of the rare diseases business.

Both Sibold and Vivaldi will report to Genzyme president and CEO David Meeker, who recently became part of the company's executive team.

August 11, 2011
Avanir sues Par, Actavis over generic versions of neurological drug

Drug maker Avanir Pharmaceuticals has filed suit against two generic drug makers seeking to launch versions of a drug used to treat pseudobulbar affect, which causes sudden, involuntary episodes of laughing and crying, and occurs secondary to numerous other neurological conditions.

ALISO VIEJO, Calif. — Drug maker Avanir Pharmaceuticals has filed suit against two generic drug makers seeking to launch versions of a drug used to treat pseudobulbar affect, which causes sudden, involuntary episodes of laughing and crying, and occurs secondary to numerous other neurological conditions.

Avanir filed the suit in the U.S. District Court for the District of Delaware against Par and Actavis, which had filed for regulatory approval of Nuedexta (dextromethorphan hydrobromide and quinidine sulfate).